Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...

Professor Markus Sauer from the Biocentre of Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...